Arenas APD-791 in Phase Ib for Arterial Thrombosis « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Arenas APD-791 in Phase Ib for Arterial Thrombosis

Posted on July 9, 2008 by crimsoncanary

Arenas APD-791 has been found to be well tolerated in a Phase Ib trial for Arterial Thrombosis. The drug dose-dependently inhibited of serotonin-mediated amplification of platelet aggregation

Filed under: Uncategorized | Tagged: 5-HT2A, 5HT2A, agonist, Arena, Inverse, phase I, Phase Ib

« Palonosetron (Aloxi) available in US for postoperative nausea and vomiting Polyphor complete Phase I trial of CXCR4 inhibitor POL6326 »

Leave a Reply